New imaging reveals how CS1 drug may reshape lung arteries in PAH patients
NCT ID NCT06907693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the drug CS1 changes the structure of small lung arteries in people with pulmonary arterial hypertension (PAH). Seven patients already taking CS1 in an expanded access program had special CT scans at the start and after 12 months. The goal was to see if CS1 can help reverse harmful blood vessel changes, which could improve treatment for PAH.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Prisma Health
Greenville, South Carolina, 29605, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests